10 Bold Solutions to End Cancer: City of Hope’s Plan
City of Hope, a leading cancer research and treatment organization, has outlined strategies to combat rising cancer rates, particularly...
FDA Approves Susvimo for Diabetic Blindness
The FDA approved Susvimo (ranibizumab injection) for diabetic macular edema (DME), a leading cause of vision loss. This marks...
Auron Therapeutics Announces FDA Clearance and Series B Financing
Auron Therapeutics, a clinical-stage biotech company, announced progress on its lead KAT2A/B program and candidate AUTX-703, along with a...
FLT201 Gene Therapy Shows Promise in Gaucher Disease Trial
Spur Therapeutics released positive Phase 1/2 trial data for FLT201, a gene therapy for Gaucher disease type 1. The...
SiteOne Announces Positive Phase 1 Data for Novel Non-Opioid Pain Drug
SiteOne Therapeutics announced positive Phase 1 clinical trial results for STC-004, its lead NaV1.8 inhibitor for non-opioid pain treatment....
Aclaris Announces Fully Funded Clarity Trial for Nociscan
Aclarion, Inc. (Nasdaq: ACON, ACONW) has secured approximately $20 million to fully fund its pivotal CLARITY trial. This trial...
CD47 Inhibitor Drugs Market 2028: 100+ Clinical Trials & Opportunities
The report “Global CD47 Inhibitor Drug Clinical Trials Insight & Market Opportunity Outlook 2028” explores the burgeoning field of...
Nexalin’s Breakthrough DIFS™ Device Reduces Blood Pressure, Improves Mental Health
Nexalin Technology, Inc. announced positive results from a clinical study published in the Journal of Affective Disorders, showing its...
Tenaya Therapeutics Gets $8M Grant for Heart Failure Research
Tenaya Therapeutics received an $8 million grant from the California Institute for Regenerative Medicine (CIRM) to fund its Phase...
Seclidemstat and Azacitidine Trial for Hematologic Cancers Patient Enrollment Resumes
Salarius Pharmaceuticals (Nasdaq: SLRX) has announced the resumption of patient enrollment in a Phase 1/2 clinical trial at MD...